Bristol Myers joins the legal fight over incoming Medicare drug price negotiations
Bristol Myers Squibb late last week joined Merck and the US Chamber of Commerce in challenging the Biden administration’s signature drug pricing reform — allowing, for …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.